Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy

被引：0
|
作者：
Nermine H. Zakaria
Doaa Hashad
Marwa H. Saied
Neamat Hegazy
Alyaa Elkayal
Eman Tayae
机构：
[1] University of Alexandria,Department of Clinical and Chemical Pathology, Faculty of Medicine
[2] University of Alexandria,Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine
来源：
Human Genomics | / 17卷
关键词：
HER2-positive breast cancer; Genetic variants; NGS; Trastuzumab; Drug resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
    Zakaria, Nermine H.
    Hashad, Doaa
    Saied, Marwa H.
    Hegazy, Neamat
    Elkayal, Alyaa
    Tayae, Eman
    HUMAN GENOMICS, 2023, 17 (01)
  • [2] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    BREAST CARE, 2021, 16 (03)
  • [4] Continued trastuzumab therapy for patients with HER2-positive breast cancer
    Haslbauer, F.
    EJC SUPPLEMENTS, 2008, 6 (07): : 221 - 221
  • [5] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
  • [6] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Gabriella Mariani
    Angelica Fasolo
    Elena De Benedictis
    Luca Gianni
    Nature Clinical Practice Oncology, 2009, 6 : 93 - 104
  • [7] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 365 - 365
  • [8] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [9] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [10] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Mortimer, Joanne
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 662 - 663
12345